Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P F Pollack

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Regulatory Peptides|March 1, 1987
Effects of enterally fed epidermal growth factor on the small and large intestine of the suckling ratP F Pollack, T Goda, P C Colony, et al.
The Journal of Pediatrics|September 1, 1976
Necrotizing enterocolitis in term infantsR A Polin, P F Pollack, B Barlow, et al.
Alimentary Pharmacology & Therapeutics|October 19, 2013
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERER Panaccione, J-F Colombel, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|June 8, 2011
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's diseaseM A Kamm, S B Hanauer, R Panaccione, et al.
Alimentary Pharmacology & Therapeutics|March 20, 2010
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's diseaseR Panaccione, J-F Colombel, W J Sandborn, et al.
Journal of Crohn'S & Colitis|June 19, 2012
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's diseaseS Schreiber, W Reinisch, J F Colombel, et al.
Current Medical Research and Opinion|February 27, 2013
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's diseaseW J Sandborn, J-F Colombel, G D'Haens, et al.
Gut|February 15, 2007
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialW J Sandborn, S B Hanauer, P Rutgeerts, et al.
Gut|February 10, 2009
Adalimumab for the treatment of fistulas in patients with Crohn's diseaseJ-F Colombel, D A Schwartz, W J Sandborn, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Regulatory Peptides|March 1, 1987
Effects of enterally fed epidermal growth factor on the small and large intestine of the suckling ratP F Pollack, T Goda, P C Colony, et al.
The Journal of Pediatrics|September 1, 1976
Necrotizing enterocolitis in term infantsR A Polin, P F Pollack, B Barlow, et al.
Alimentary Pharmacology & Therapeutics|October 19, 2013
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERER Panaccione, J-F Colombel, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics|June 8, 2011
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's diseaseM A Kamm, S B Hanauer, R Panaccione, et al.
Alimentary Pharmacology & Therapeutics|March 20, 2010
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's diseaseR Panaccione, J-F Colombel, W J Sandborn, et al.
Journal of Crohn'S & Colitis|June 19, 2012
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's diseaseS Schreiber, W Reinisch, J F Colombel, et al.
Current Medical Research and Opinion|February 27, 2013
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's diseaseW J Sandborn, J-F Colombel, G D'Haens, et al.
Gut|February 15, 2007
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialW J Sandborn, S B Hanauer, P Rutgeerts, et al.
Gut|February 10, 2009
Adalimumab for the treatment of fistulas in patients with Crohn's diseaseJ-F Colombel, D A Schwartz, W J Sandborn, et al.
Pageof 2